• Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study
• The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market
• The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy”
• It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim results from its WEIGHT-A24-1 animal study. The study evaluated the company’s patented DehydraTECH technology and its potential to address diabetes and weight loss. The first four weeks of dosing was successful, with Lexaria’s management describing its findings as “noteworthy” (https://cnw.fm/nRqEL).

The first phase of this study involved eight study arms, four of which used varying compositions of DehydraTECH-processed CBD. Two of the arms used reformulated Rybelsus(R) composition, which included DehydraTECH and sodium salcaprozate (“SNAC”) technology. In contrast, the last two used…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

This press release is distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lexaria Bioscience (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study.